TY - JOUR
T1 - Revisiting Parkinson’s Disease Treatment: Exploring Established Medications and Emerging Therapies
AU - Daniel Brooks
AU - Amelia Carter
AU - Ethan Moore
AU - Olivia Grant
JF - EAMD 3
Y1 - 0
VL - 0
IS - 0
SP - 90
N2 - Parkinson’s disease (PD) is a chronic and progressive neurodegenerative condition characterized by motor impairments such as tremors and stiffness, along with non-motor symptoms including cognitive decline and depression. While current dopaminergic therapies help manage symptoms, they do not halt the progression of the disease, underscoring the urgent need for treatments that can modify its course. This review explores the potential of repurposing drugs from diverse therapeutic categories—such as immunomodulators, cardiometabolic agents, and anti-infectives—to treat PD. Immunomodulatory compounds such as c-Abl inhibitors (e.g., imatinib and nilotinib) and sargramostim have shown potential to reduce α-synuclein buildup and brain inflammation, though clinical outcomes have been inconsistent. Among cardiometabolic drugs, glucagon-like peptide-1 (GLP-1) receptor agonists, such as exenatide, have shown promising results in improving motor and cognitive function, with phase III trials currently investigating their ability to slow disease progression. Some anti-infective agents, including doxycycline and rifampicin, offer neuroprotective benefits through anti-inflammatory and anti-aggregation mechanisms. Despite ongoing concerns regarding their effectiveness and potential side effects, these repurposed drugs represent promising avenues for PD treatment. Moreover, emerging strategies such as gene therapy, enzyme replacement therapy, and advanced drug-delivery technologies aim to target the underlying disease mechanisms directly. Although no definitive disease-modifying treatment exists yet, the investigation of repurposed and novel therapies provides optimism for future advancements. Further large-scale clinical studies are essential to confirm their safety and therapeutic value.
UR - https://pubsys.eshragh.co/i340840675
ER -